Aastrom Announces Investor Conference Call and Webcast June 16, 2014 at 8:30 AM EDT
June 15 2014 - 6:00PM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, will hold an investor conference
call and slide presentation on Monday, June 16, 2014 beginning at
8:30 AM EDT. The company will present an update and its strategic
plans for the cell therapy and regenerative medicine business that
it recently acquired from Sanofi.
What: |
Aastrom Biosciences, Inc., Investor
Conference Call and Webcast |
|
|
When: |
Monday, June 16, 2014, at 8:30 AM (EDT) |
|
|
How: |
The conference call will be available live in
the Investors section of the Aastrom website at
http://investors.aastrom.com/events.cfm. |
|
Please access the site at least 15 minutes
prior to the scheduled start time in order to download the slide
presentation and, if necessary, the required audio
software. |
|
|
|
To participate in the live call by telephone,
please call (877) 312-5881 and reference Aastrom Biosciences
Conference Call. If calling from outside the U.S., please use the
international phone number (253) 237-1173. |
If you are unable to participate during the live call, a replay
of the call will be available beginning June 16, 2014 at 11:30 AM
(EDT) until June 20, 2014 at 11:59 PM (EDT) by calling (855)
859-2056, or from outside the U.S. by calling (404) 537-3406. The
conference ID is 61387590. A copy of the presentation slides will
be available in the Investors section of the Aastrom website at
http://investors.aastrom.com/events.cfm.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing patient-specific
expanded cellular therapies for use in the treatment of patients
with severe diseases and conditions. Aastrom markets two autologous
cell therapy products in the United States for the treatment of
cartilage repair and skin replacement, and is developing
ixmyelocel-T, a patient-specific multicellular therapy for the
treatment of advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit Aastrom's
website at www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning anticipated progress,
objectives and expectations regarding profitability, growth in
revenue and earnings per share, cash payments, the costs and
expenses as well as expected benefits and cost savings that we
anticipate will result from the strategic restructuring plan
described herein, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent risks and uncertainties associated
with competitive developments, estimating profitability, cash
payments, growth in revenues and earnings per share prior to us
closing our books and verifying such information, our ability to
successfully implement the strategic restructuring plan described
herein to reduce expenses and produce cost savings, leverage
synergies and optimize our resources, the impact of the strategic
restructuring plan described herein on our business, regulatory and
product development activities as well as potential adverse effects
on revenues and other financial results, or unanticipated charges
not currently contemplated that may occur as a result of the
strategic restructuring plan described herein. These and other
significant factors are discussed in greater detail in Aastrom's
Annual Report on Form 10-K for the year ended December 31, 2013,
filed with the Securities and Exchange Commission ("SEC") on March
13, 2014, Quarterly Reports on Form 10-Q and other filings with the
SEC. These forward-looking statements reflect management's current
views and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Media contact:
David Salisbury
Berry & Company
dsalisbury@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Apr 2023 to Apr 2024